Overview

Oxaliplatin and S-1 (OS) Versus Oxaliplatin and Capecitabine (XELOX) for Advanced Colorectal Cancer

Status:
Completed
Trial end date:
2012-04-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to compare the activity and safety of Oxaliplatin and S-1 (OS) and Oxaliplatin and Capecitabine (XELOX) in patients with advance or recurrent colorectal cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Hallym University Medical Center
Collaborator:
Sanofi
Treatments:
Capecitabine
Oxaliplatin